日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Cefiderocol in Chinese Healthy Subjects

头孢地洛在中国健康受试者中的药代动力学、药代动力学/药效学和安全性研究

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-025-03147-1
Zhang, Chuhan; Yu, Shuyan; Li, Size; Wu, Xiaojie; Wei, Qiong; He, Jinjie; Cao, Guoying; Yang, Haijing; Wang, Jingjing; Fujitani, Kohei; Katsube, Takayuki; Zhang, Jing; Dou, Honghong
发表日期：2025
文献求助 收藏

First-in-Human Study of BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody in Patients With Neuromyelitis Optica Spectrum Disorders

BAT4406F（一种ADCC增强型全人源化抗CD20单克隆抗体）在视神经脊髓炎谱系疾病患者中的首次人体研究

期刊:CNS Neuroscience & Therapeutics
影响因子:5
doi:10.1111/cns.70126
Yu, Hai; Chen, Yuancheng; Qi, Yunpeng; Yang, Haijing; Cao, Guoying; Yang, Wenbo; Li, Size; Yang, Xiaolei; Wang, Hai; Zhang, Jing; Chen, Xiangjun
单克隆抗体
DCC
神经科学
CD20
Human
CD2
发表日期：2024
文献求助 收藏

Lefamulin dosing optimization using population pharmacokinetic and pharmacokinetic/pharmacodynamic assessment in Chinese patients with community-acquired bacterial pneumonia

利用群体药代动力学和药代动力学/药效学评估方法优化来法莫林在中国社区获得性细菌性肺炎患者中的给药剂量

期刊:Frontiers in Pharmacology
影响因子:4.8
doi:10.3389/fphar.2024.1456741
Bian, Xingchen; Li, Nanyang; Li, Yi; Zhu, Xu; Yu, Jicheng; Hu, Yingying; Yang, Haijing; Wei, Qiong; Wu, Xiaojie; Wang, Jingjing; Cao, Guoying; Wu, Jufang; Wang, Yang; Zhang, Jing
肺炎
微生物学
发表日期：2024
文献求助 收藏

First-in-human study to evaluate the safety, tolerability, and population pharmacokinetic/pharmacodynamic target attainment analysis of FL058 alone and in combination with meropenem in healthy subjects

首次人体研究，旨在评估 FL058 单药治疗及与美罗培南联合用药在健康受试者中的安全性、耐受性和群体药代动力学/药效学目标达成情况。

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/aac.01330-23
Huang, Zhiwei; Yang, Xinyi; Jin, Yi; Yu, Jicheng; Cao, Guoying; Wang, Jingjing; Hu, Yingying; Dai, Jingyi; Wu, Jufang; Wei, Qiong; Tian, Yan; Yu, Shuyan; Zhu, Xu; Mao, Xiaomeng; Liu, Wei; Liang, Hong; Zheng, Shansong; Ju, Yunfei; Wang, Zenghua; Zhang, Jing; Wu, Xiaojie
发表日期：2024
文献求助 收藏

Erratum for Yang et al., "A phase I study of the safety, tolerability, and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects"

更正：Yang 等人，“康替唑利德醋福沙米在健康中国受试者中静脉注射和口服给药后的安全性、耐受性和药代动力学 I 期研究”

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/aac.00506-24
Yang, Haijing; Jin, Yi; Wang, Hailin; Yuan, Hong; Wang, Jingjing; Li, Size; Hu, Yingying; Yang, Huahui; Li, Xin; Liang, Hong; Wu, Jufang; Cao, Guoying; Zhang, Jing
发表日期：2024
文献求助 收藏

Pharmacokinetics and safety of EVER206, a novel polymyxin antimicrobial, in healthy Chinese subjects

EVER206（一种新型多粘菌素类抗菌药物）在健康中国受试者中的药代动力学和安全性研究

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/aac.01563-23
Li, Size; Zhu, Xu; Cao, Guoying; Shen, Jufang; Zhu, Xu; Yu, Jicheng; Wu, Xiaojie; Wu, Jufang; Yang, Haijing; Li, Nanyang; Hu, Yingying; Wang, Jingjing; Huang, Haihui; Zhang, Jing
发表日期：2024
文献求助 收藏

Pharmacokinetics and safety of mavacamten in healthy Chinese participants with different CYP2C19 phenotypes

不同CYP2C19表型健康中国受试者中马伐卡坦的药代动力学和安全性

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.13877
Wu, Xiaojie; Chen, Nanye; Hsu, Peiwen; Sun, Jing; Li, Wenting; Wang, Qi; Samira, Merali; Wei, Qiong; Yu, Jicheng; Cao, Guoying; Yang, Haijing; Wang, Lili; Wang, Jingjing; Jin, Yi; Liu, Wei; Wu, Jufang; He, Jinjie; Lyu, Cheng; Zhang, Jing
发表日期：2024
文献求助 收藏

Pharmacokinetic and safety profiles of mesalazine enema in healthy Chinese subjects: A single- and multiple-dose study

美沙拉嗪灌肠剂在健康中国受试者中的药代动力学和安全性特征：单次和多次给药研究

期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0296940
Cao, Yuran; Wang, Jingjing; Tang, Xingyu; Tian, Yan; Yu, Jicheng; Liang, Hong; Wu, Jufang; Chen, Yuancheng; Cao, Guoying; Zhang, Jing
发表日期：2024
文献求助 收藏

A Randomized, Parallel, Open-Label, Single-Dose and Multiple-Dose Clinical Trial to Investigate the Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Obicetrapib in Healthy Participants in China

一项在中国开展的随机、平行、开放标签、单剂量和多剂量临床试验，旨在研究奥比曲匹在中国健康受试者中的药代动力学、药效学和安全性特征。

期刊:Journal of Clinical Pharmacology
影响因子:2.3
doi:10.1002/jcph.6121
Zhang, Jing; Cao, Guoying; Huo, Yong; Guarneri, Liana L; Ditmarsch, Marc; Kastelein, John J P; Kling, Douglas; Hsieh, Andrew; Wuerdeman, Erin; Davidson, Michael H
发表日期：2024
文献求助 收藏

LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA(®) in Chinese healthy male subjects

LZM008，一种拟上市的托珠单抗生物类似药：与ACTEMRA®在中国健康男性受试者中的药代动力学、安全性和免疫原性特征比较

期刊:Frontiers in Pharmacology
影响因子:4.8
doi:10.3389/fphar.2023.1111893
Cao, Guoying; Wang, Jingjing; He, Jinjie; Hu, Yingying; Yang, Haijing; Que, Linling; Gu, Xianghong; Yu, Jicheng; Wu, Xiaojie; Wu, Jufang; Fang, Wei; He, Qing; Zhang, Jing
免疫/内分泌
发表日期：2023
文献求助 收藏